De Novo · Granted
GrantedB.R.A.H.M.S PCT sensitive KRYPTOR
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Brahms GmbH · PMT Device To Detect And Measure Procalcitonin (Pct) In Human Clinical Specimens
Granted on Feb 20, 2016 as a new device type through De Novo after a 353-day review. 27 later devices descend from it.
- Decided
- Feb 20, 2016
- Review
- 353 days
- Class
- Class II
- Product code
- PMT
- Recalls
- None
27 later devices descend from it, 5 citing it directly.
- This deviceDEN150009 B.R.A.H.M.S PCT sensitive KRYPTORBrahms GmbH · 2016
- Descendant · cites it directly · 22 of its ownK160911 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016
- Descendant · 2 generations on · 21 of its ownK162827 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017
- Descendant · cites it directly · 7 of its ownK171338 B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017
- Descendant · 3 generations on · 3 of its ownK210254 MeMed BVMeMed Diagnostics, Ltd. · 2021
- Descendant · 3 generations on · 2 of its ownK220991 IntelliSep testCytovale, Inc. · 2022
Showing 5 of 27 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 27 · See all- K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016 · cites it directly22descendants
- K162827Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017 · 2 generations on21descendants
- K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017 · cites it directly7descendants
- K210254MeMed BVMeMed Diagnostics, Ltd. · 2021 · 3 generations on3descendants
- K220991IntelliSep testCytovale, Inc. · 2022 · 3 generations on2descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| 0 (this device) | DEN150009 | B.R.A.H.M.S PCT sensitive KRYPTOR | Brahms GmbH | 2016 | — |
| +1 | K160911 | Vidas B.R.a.H.M.S. PCT (PCT) | bioMerieux, Inc. | 2016 | — |
| +2 | K162827 | Vidas B.R.a.H.M.S. PCT (PCT) | bioMerieux, Inc. | 2017 | — |
| +1 | K171338 | B R A H M S PCT sensitive KRYPTOR | Brahms GmbH | 2017 | — |
| +3 | K210254 | MeMed BV | MeMed Diagnostics, Ltd. | 2021 | — |
| +3 | K220991 | IntelliSep test | Cytovale, Inc. | 2022 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2016 | 2 | 0 |
| 2017 | 5 | 0 |
| 2018 | 3 | 0 |
| 2019 | 2 | 0 |
| 2020 | 3 | 0 |
| 2021 | 2 | 0 |
| 2022 | 3 | 0 |
| 2023 | 3 | 0 |
| 2024 | 1 | 0 |
| 2025 | 3 | 0 |
Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in PMT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new PMT device
- #1 K200236 VITROS BRAHMS PCT Reagent Pack and Calibratorsscore -0.2 · 4 generations · no Class I recall
Does it have a predicate?
De Novo decisions do not claim a predicate device.
What descends from it? (27)
See all 275 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Of its descendants, K160911 (bioMerieux, Inc., 2016) has gone furthest, with 22 descendants of its own.
How does its category compare?
All PMT devicesPMT Device To Detect And Measure Procalcitonin (Pct) In Human Clinical Specimens: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.
FDA decisions per year · PMT
1in 2020
2026 to Oct 25, outlined.
Median 510(k) review, days · PMT
Too few PMT 510(k)s in any year since 2007 to give a median.
Recalls per year · PMT
No recall names PMT since 2007.
Adverse event reports per year · PMT
1in 2025
MAUDE reports naming product code PMT, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 3 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 4 |
| 2018 | 1 | — | 0 | 3 |
| 2019 | 0 | — | 0 | 1 |
| 2020 | 1 | — | 0 | 1 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 2 |
| 2024 | 0 | — | 0 | 1 |
| 2025 | 0 | — | 0 | 1 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The B· R· A· H· M· S PCT sensitive KRYPTOR is an immunofluorescent assay using Time-Resolved Amplified Cryptate Emission (TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin plasma. The B· R· A· H· M· S PCT sensitive KRYPTOR is intended to be performed on the B· R· A· H· M· S KRYPTOR analyzer family. The B· R A- H· M· S PCT sensitive KRYPTOR is intended for use in conjunction with other laboratory…
Read the full statement (411 words)
The B· R· A· H· M· S PCT sensitive KRYPTOR is an immunofluorescent assay using Time-Resolved Amplified Cryptate Emission (TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin plasma.
The B· R· A· H· M· S PCT sensitive KRYPTOR is intended to be performed on the B· R· A· H· M· S KRYPTOR analyzer family.
The B· R A- H· M· S PCT sensitive KRYPTOR is intended for use in conjunction with other laboratory fmdings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock.
The B· R· A- H- M· S PCT sensitive KRYPTOR is also intended for use to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory fmdings and clinical assessments for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission.
Procalcitonin (PCT) is a biomarker associated with the inflammatory response to bacterial infection that aids in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock. The percent change in PCT level over time also aids in the prediction of cumulative 28-day mortality in patients with severe sepsis and septic shock.
PCT level on the first day of ICU admission above 2.0 Jlg/L is associated with a higher risk for progression to severe sepsis and/or septic shock than a PCT level below 0.5 Jlg/L.
A PCT level that declines::; 80% from the day that severe sepsis or septic shock was clinically diagnosed (Day 0) to four days after clinical diagnosis (Day 4) is associated with higher cumulative 28-day risk of all-cause mortality than a decline > 80%.
The combination of the PCT level (:'0 2.0 ug!L or> 2.0 Jlg/L) at initial diagnosis of severe sepsis or septic shock with the patient's clinical course and the change in PCT level over time until Day 4 provides important additional information about the mortality risk.
The PCT level on Day I (the day after severe sepsis or septic shock is first clinically diagnosed) can be used to calculate the percent change in PCT level at Day 4 if the Day 0 measurement is unavailable.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/DEN150009 · printed Nov 6, 2026
Cite this page
510(k) Report. “DEN150009: B.R.A.H.M.S PCT sensitive KRYPTOR.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN150009
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026